TrialJournal of cosmetic dermatology2025

Efficacy and Safety of CKDB-501A in Treating Moderate-To-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center Phase III Trial.

Sun Young Choi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.